Literature DB >> 28822614

Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management.

Jonathan C P Roos1, Matthew J Daniels1, Elizabeth Morris1, Hanna I Hyry1, Timothy M Cox2.   

Abstract

BACKGROUND: Danon disease is an X-linked disturbance of autophagy manifesting with cognitive impairment and disordered heart and skeletal muscle. After a period of relative stability, patients deteriorate rapidly and may quickly become ineligible for elective heart transplantation - the only life-saving therapy.
METHODS: We report a large pedigree with diverse manifestations of Danon disease in hemizygotes and female heterozygotes.
RESULTS: Malignant cardiac arrhythmias requiring amiodarone treatment induced thyroid disease in two patients; intractable thyrotoxicosis, which enhances autophagy, caused the death of a 21year-old man. Our patients also had striking elevation of serum troponin I during the accelerated phase of their illness (p<0.01) and rising concentrations heralded cardiac decompensation. We argue for changes to cardiac transplantation eligibility criteria.
CONCLUSION: Danon disease causes hypertrophic cardiomyopathy - here we propose a common pathophysiological basis for the metabolic and structural effects of this descriptive class of heart disorders. We also contend that troponin I may have prognostic value and merits exploration for clinical decision-making including health warning bracelets. Rapamycin (Sirolimus®), an approved immunosuppressant which also influences autophagy, may prove beneficial. In the interim, while new treatments are developed, a revaluation of cardiac transplantation eligibility criteria is warranted.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autophagy; Danon disease; Hypertrophic cardiomyopathy; LAMP2; Learning difficulties; Obesity; Rapamycin; Thyrotoxicosis; Troponin

Mesh:

Substances:

Year:  2017        PMID: 28822614      PMCID: PMC6588538          DOI: 10.1016/j.ymgme.2017.06.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  44 in total

1.  Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts.

Authors:  Thomas Lücke; Wiebke Höppner; Esther Schmidt; Sabine Illsinger; Anibh M Das
Journal:  Mol Genet Metab       Date:  2004-05       Impact factor: 4.797

2.  Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure.

Authors:  Eldrin F Lewis; Sui W Tsang; James C Fang; Gilbert H Mudge; John A Jarcho; Carol M Flavell; Anju Nohria; Michael M Givertz; Gregory S Couper; John G Byrne; Lynne Warner Stevenson
Journal:  J Am Coll Cardiol       Date:  2004-03-03       Impact factor: 24.094

3.  Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis.

Authors:  E Blair; C Redwood; H Ashrafian; M Oliveira; J Broxholme; B Kerr; A Salmon; I Ostman-Smith; H Watkins
Journal:  Hum Mol Genet       Date:  2001-05-15       Impact factor: 6.150

4.  Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).

Authors:  I Nishino; J Fu; K Tanji; T Yamada; S Shimojo; T Koori; M Mora; J E Riggs; S J Oh; Y Koga; C M Sue; A Yamamoto; N Murakami; S Shanske; E Byrne; E Bonilla; I Nonaka; S DiMauro; M Hirano
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

5.  Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia.

Authors:  J L Bradley; J C Blake; S Chamberlain; P K Thomas; J M Cooper; A H Schapira
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

6.  Frataxin activates mitochondrial energy conversion and oxidative phosphorylation.

Authors:  M Ristow; M F Pfister; A J Yee; M Schubert; L Michael; C Y Zhang; K Ueki; M D Michael; B B Lowell; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

7.  Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey.

Authors:  P Charron; E Villard; P Sébillon; P Laforêt; T Maisonobe; L Duboscq-Bidot; N Romero; V Drouin-Garraud; T Frébourg; P Richard; B Eymard; M Komajda
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

8.  A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy.

Authors:  Robert W Taylor; Carla Giordano; Mercy M Davidson; Giulia d'Amati; Hugh Bain; Christine M Hayes; Helen Leonard; Martin J Barron; Carlo Casali; Filippo M Santorelli; Michio Hirano; Robert N Lightowlers; Salvatore DiMauro; Douglass M Turnbull
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

Review 9.  Clinicopathological features of genetically confirmed Danon disease.

Authors:  K Sugie; A Yamamoto; K Murayama; S J Oh; M Takahashi; M Mora; J E Riggs; J Colomer; C Iturriaga; A Meloni; C Lamperti; S Saitoh; E Byrne; S DiMauro; I Nonaka; M Hirano; I Nishino
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  6 in total

1.  Phenotyping an adult zebrafish lamp2 cardiomyopathy model identifies mTOR inhibition as a candidate therapy.

Authors:  Alexey V Dvornikov; Mingmin Wang; Jingchun Yang; Ping Zhu; Tai Le; Xueying Lin; Hung Cao; Xiaolei Xu
Journal:  J Mol Cell Cardiol       Date:  2019-06-20       Impact factor: 5.000

2.  A Nationwide Survey on Danon Disease in Japan.

Authors:  Kazuma Sugie; Hirofumi Komaki; Nobuyuki Eura; Tomo Shiota; Kenji Onoue; Hiroyasu Tsukaguchi; Narihiro Minami; Megumu Ogawa; Takao Kiriyama; Hiroshi Kataoka; Yoshihiko Saito; Ikuya Nonaka; Ichizo Nishino
Journal:  Int J Mol Sci       Date:  2018-11-08       Impact factor: 5.923

3.  Comment: Why are females with Fabry disease affected?

Authors:  Michael Beck; Timothy M Cox
Journal:  Mol Genet Metab Rep       Date:  2019-10-22

Review 4.  Hypertrophic Cardiomyopathy in Children: Pathophysiology, Diagnosis, and Treatment of Non-sarcomeric Causes.

Authors:  Emanuele Monda; Marta Rubino; Michele Lioncino; Francesco Di Fraia; Roberta Pacileo; Federica Verrillo; Annapaola Cirillo; Martina Caiazza; Adelaide Fusco; Augusto Esposito; Fabio Fimiani; Giuseppe Palmiero; Giuseppe Pacileo; Paolo Calabrò; Maria Giovanna Russo; Giuseppe Limongelli
Journal:  Front Pediatr       Date:  2021-02-25       Impact factor: 3.569

Review 5.  Danon disease: a case report and literature review.

Authors:  Jiamin Xu; Zhu Li; Yihai Liu; Xinlin Zhang; Fengnan Niu; Hongyan Zheng; Lian Wang; Lina Kang; Kun Wang; Biao Xu
Journal:  Diagn Pathol       Date:  2021-05-01       Impact factor: 3.196

6.  A case report of delayed diagnosis of danon disease: Caused by a newly recognized mutation in the lysosome-associated membrane protein-2 gene.

Authors:  Ying Zhang; Hang Ren; Shanshan Zhou
Journal:  Medicine (Baltimore)       Date:  2020-10-02       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.